You are here

Article Text

Article menu
Download PDFPDF
Concise report
β Thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis
  1. O Kowal-Bielecka1,
  2. K Kowal2,
  3. A Lewszuk3,
  4. A Bodzenta-Lukaszyk2,
  5. J Walecki3,
  6. S Sierakowski1
  1. 1Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland
  2. 2Department of Allergology and Internal Diseases, Medical University of Bialystok
  3. 3Department of Radiology, Medical University of Bialystok
  1. Correspondence to:
    Dr Otylia Kowal-Bielecka
    Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Ul M Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland; otyliaamb.edu.pl

Abstract

Objective: To evaluate concentrations of the platelet activation markers β thromboglobulin (BTG) and platelet factor 4 (PF4) in bronchoalveolar lavage fluid (BALF) from patients with systemic sclerosis with and without scleroderma interstitial lung disease (SLD).

Methods: BTG and PF-4 were measured by enzyme immunoassay in BALF from 37 patients with systemic sclerosis. Controls were 10 healthy subjects. BALF was collected during routine bronchoscopy from the right middle lobe. SLD was diagnosed by high resolution computed tomography of the lungs.

Results: BTG was detected in 11 of the patients with systemic sclerosis (29.7%) and PF4 was found in eight (21.6%). Mean (SD) concentrations of BTG and PF4 in BALF from patients with detectable levels of these platelet activation markers were 106.9 (69.8) and 35.2 (17.4) IU/ml, respectively. The BTG:PF4 ratio was more than 2:1, indicating in vivo release. Both markers were found exclusively in patients with SLD. SLD patients with detectable platelet activation markers had a significantly shorter disease duration than those with undetectable BTG/PF4.

Conclusions: The study provides evidence that activation of blood platelets takes place within the lungs of patients with SLD and may contribute to the development of lung fibrosis.

  • BALF, bronchoalveolar lavage fluid
  • BTG, β thromboglobulin
  • FVC, forced vital capacity
  • HRCT, high resolution computed tomography
  • NSAID, non-steroidal anti-inflammatory drug
  • PF4, platelet factor 4
  • SLD, scleroderma interstitial lung disease
  • scleroderma lung disease
  • systemic sclerosis
  • β thromboglobulin
  • platelet factor 4

https://doi.org/10.1136/ard.2004.022970

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes